Welcome to The Visible Embryo
  o
 
The Visible Embryo Birth Spiral Navigation
   
Google  
Fetal Timeline--- -Maternal Timeline-----News-----Prescription Drugs in Pregnancy---- Pregnancy Calculator----Female Reproductive System

   
WHO International Clinical Trials Registry Platform

The World Health Organization (WHO) has a Web site to help researchers, doctors and patients obtain information on clinical trials.

Now you can search all such registers to identify clinical trial research around the world!






Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

News

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.


Content protected under a Creative Commons License.
No dirivative works may be made or used for commercial purposes.

 

Pregnancy Timeline by SemestersDevelopmental TimelineFertilizationFirst TrimesterSecond TrimesterThird TrimesterFirst Thin Layer of Skin AppearsEnd of Embryonic PeriodEnd of Embryonic PeriodFemale Reproductive SystemBeginning Cerebral HemispheresA Four Chambered HeartFirst Detectable Brain WavesThe Appearance of SomitesBasic Brain Structure in PlaceHeartbeat can be detectedHeartbeat can be detectedFinger and toe prints appearFinger and toe prints appearFetal sexual organs visibleBrown fat surrounds lymphatic systemBone marrow starts making blood cellsBone marrow starts making blood cellsInner Ear Bones HardenSensory brain waves begin to activateSensory brain waves begin to activateFetal liver is producing blood cellsBrain convolutions beginBrain convolutions beginImmune system beginningWhite fat begins to be madeHead may position into pelvisWhite fat begins to be madePeriod of rapid brain growthFull TermHead may position into pelvisImmune system beginningLungs begin to produce surfactant
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development




 

A vaccine that could prevent Type 1 Diabetes

A research group at the University of Tampere in Helsinki, Sweden, has long pioneered the development of a vaccine to prevent Type 1 Diabetes. They have now identified the enteroviruses belonging to a group B coxsackieviruses that are related to diabetes, and a prototype vaccine has been developed to prevent these viruses from initiating diabetes in pancreas cells.


“It is already known that the vaccine is effective and safe on mice. The developing process has now taken a significant leap forward as the next phase is to study the vaccine in humans,” says Heikki Hyöty PhD, Professor of Virology at Tampere University in Helsinki, Finland and leader of the research.

The vaccine is to be studied in a small group of adults in its first clinical phase, to ensure its safety. In the second phase, the vaccine will be studied in children to investigate its safety and effectiveness against enteroviruses, which include polio virus and any picornaviruses that usually infect the gastrointestinal tract. In the third phase will test whether the vaccine prevents the onset of Type 1 Diabetes. The entire series of tests will take about eight years before there is any certainly the vaccine does prevent Type 1 Diabetes.
“The aim was to develop a vaccine that could prevent a significant number of Type 1 Diabetes cases. Additionally, the vaccine would protect from infections caused by enteroviruses such as the common cold, myocarditis, meningitis and ear infections. However, in light of current research, the vaccine could not be used to cure pre-existing diabetes.”

Heikki Hyöty PhD, Professor of Virology, Tampere University, Helsinki, Finland and leader of the research.

Type 1 Diabetes is caused by the destruction of insulin-producing cells in the pancreas, and is treated with daily insulin injections. Type 1 Diabetes is becoming more common and cases of it occur in Finland more than anywhere else in the world. It places a significant burden on public health care and can reduce the quality of life and the average life expectancy. It has been estimated that a patient with Type 1 Diabetes will cause society expenses worth 1 million EUROs on average during their lifetime.

The connection between viral infections and Type 1 Diabetes has been researched for over 25 years at the Faculty of Medicine and Life Sciences at the University of Tampere. Their results indicate that one virus group, enteroviruses, play a part in developing Type 1 Diabetes which can infect the insulin-producing cells of the pancreas damaging them permanently.

The research phase beginning now is the result of a long period of negotiations between several stakeholders. It will be funded by the US-based company Provention Bio. Other partners include The Juvenile Diabetes Research Foundation, the largest foundation funding research on Type 1 Diabetes in the world, and Vactech Oy a Finnish company that has developed the necessary vaccine technology. Professor Heikki Hyöty (University of Tampere) and Professor Mikael Knip (University of Helsinki) are co-founders in Vactech Oy.

Introduction
Type 1 diabetes is caused by an immune-mediated process that damages insulin-producing beta cells in the pancreatic islets. The subclinical phase of the disease can be identified by detecting autoantibodies against islet antigens, including islet cell antibodies (ICAs), insulin antibodies (IAAs), insulinoma-associated protein 2 antibodies (IA-2As), zinc transporter 8 antibodies and GAD antibodies [1].

Enteroviruses have been linked to type 1 diabetes in studies showing an increased frequency of these viruses in the blood and pancreas of diabetic and autoantibody-positive individuals [2, 3, 4] and in serological studies showing an increased frequency of enterovirus antibodies in diabetic and autoantibody-positive participants [5, 6, 7, 8, 9, 10, 11]. However, this association has not been seen in all studies [8].

Relatively few prospective studies have been carried out even though such studies would be optimal for evaluating the possible role of enterovirus infections in the most important phase of pathogenesis, the initiation of islet autoimmunity. The results from such studies have suggested that enterovirus infections, diagnosed by serology or by direct detection of the virus from blood, are associated with the appearance of islet autoantibodies long before clinical diabetes is diagnosed [6, 9, 11, 12]. In contrast, the detection of the virus in stools has not shown such an association [13, 14], and in one study in which both blood and rectal swabs were analysed, no association at all was found [15]. However, these negative findings have been based on small cohorts and infrequent sample collection. In addition, the Diabetes and Autoimmunity Study in the Young (DAISY) study in the USA has evaluated the possible role of enterovirus infection in the progression of islet autoimmunity to clinical disease and reported more enterovirus infections detected by the presence of virus in blood but not in stools in children who progressed to diabetes [16].

The current study is the largest to date in which enteroviruses have been analysed in longitudinal stool samples collected from children who developed signs of a beta cell-damaging process during their prospective observation. Since this study was based on a prospective birth cohort, we were able to analyse time-dependent associations between enterovirus infections and the initiation of the beta cell-damaging process.

Keywords: TERRA, R-loop, RNA-DNA hybrid, RNase H2, telomere, DDR, senescence, Rat1, Rif2


Finnish research played a key role along with the Type 1 Diabetes Prediction and Prevention study (DIPP) which has significantly advanced research on a connection between viruses and diabetes. Additionally, collaboration with Vesa Hytönen PhD, Assistant Professor and other Tampere-based professionals, has been crucial in developing vaccines. Other noteworthy partners include the Karolinska Institutet in Stockholm, several universities and research institutes in Finland and abroad as well as Vactech Oy. Research has been funded by several different groups, such as the Academy of Finland, TEKES, the Sigrid Juselius Foundation, the Reino Lahtikari Foundation, the Diabetes Research Foundation, the European Union and the Juvenile Diabetes Research Foundation (JDRF).

Related Research:
Clinical Tirals.gov

The Massachusetts General Hospital Immunobiology Laboratory conducts basic and translational research focused on discovering novel treatments for autoimmune diseases, with a specific focus on type 1 diabetes.
The Massachusetts General Hospital Immunobiology Laboratory

Return to top of page

Jul 24, 2017   Fetal Timeline   Maternal Timeline   News   News Archive




Enterovirus in pancreatic tissue, stained brown.
Image Credit: Heikki Hyöty PhD, Tampere University, Helsinki, Finland



Phospholid by Wikipedia